HM8: Regulatory mechanisms to expedite drug development and patient access (e.g. PRIME)


Many regions and countries have regulatory frameworks that can be applied to potentially bring medicines to patients in an expedited way, for example, fast track and breakthrough designations in the US and the accelerated assessment or PRIME designation in the EU. Usually, such mechanisms are applied to address unmet medical needs for serious or life-threatening diseases or conditions, and bring several benefits such as, expedited development and review, rolling reviews or intensive guidance during development.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member